Table 3:

Linear regression of the normalized WMF, GMF, CSFF, NF, and BPF of the control and the MS groups as a function of agea

WMFGMFCSFFNFBPF
Contr1-age (%/yr)−0.12 (−0.21 to −0.03)b−0.03 (−0.11–0.05)0.17 (0.07–0.27)c−0.01 (−0.03–0.01)−0.17 (−0.27 to −0.07)c
Contr2-age (%/yr)−0.10 (−0.19 to −0.01)b−0.05 (−0.12–0.03)0.17 (0.07–0.27)c−0.02 (−0.05–0.02)−0.17 (−0.2 to −0.07)c
MS1-age (%/yr)−0.02 (−0.26–0.22)−0.03 (−0.16–0.10)0.05 (−0.13–0.23)0.00 (−0.08–0.07)−0.05 (−0.23, −0.13)
MS2-age (%/yr)−0.01 (−0.31–0.30)−0.05 (−0.25–0.15)0.04 (−0.14–0.23)0.02 (−0.06–0.09)−0.04 (−0.23–0.14)
MS1-EDSS (%/unit)−1.16 (−2.28 to −0.05)b−0.17 (−0.87–0.54)0.93 (−0.19–2.04)0.23 (−0.14–0.62)−1.08 (−1.90 to −0.26)b
MS2-EDSS (%/unit)−1.34 (−2.81–0.13)0.09 (−1.01–1.19)0.93 (−0.19–2.06)0.19 (−0.20–0.58)−1.06 (−1.92 to −0.20)b
  • Note:—Contr indicates control group; MS, MS patient group; 1, measurement 1; 2, measurement 2; WMF, WM fraction; GMF, GM fraction; CSFF, CSF fraction; NF, remaining, unclassified non-WM/GM/CSF tissue fraction; BPF, brain parenchymal fraction.

  • a The 95% confidence interval is given between parentheses. For the MS group, the linear regression of the age-corrected fractions with EDSS is provided.

  • b P < .05 (significant difference).

  • c P < .005 (significant difference).